查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
原发性进行性多发性硬化症治疗药的全球市场 (2022-2031年):药物类型 (已通过核准药·开发平台药物)·流通管道 (零售药局·电子商务) 别市场规模·占有率·成长·趋势·预测
市场调查报告书
商品编码
1208547

原发性进行性多发性硬化症治疗药的全球市场 (2022-2031年):药物类型 (已通过核准药·开发平台药物)·流通管道 (零售药局·电子商务) 别市场规模·占有率·成长·趋势·预测

Primary Progressive Multiple Sclerosis Treatment Market (Drug Type: Approved Drugs & Pipeline Drugs; & Distribution Channel: Retail Pharmacies, E-commerce, & Others) - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

本报告提供全球原发性进行性多发性硬化症治疗药的市场调查，彙整市场概要，市场成长的各种影响因素分析，开发平台分析，市场规模的转变·预测，各种区分·地区/各主要国家的明细，竞争环境，市场占有率，主要企业简介等资讯。

目录

第1章 序文

第2章 前提与调查手法

第3章 摘要整理:全球原发性进行性多发性硬化症治疗药市场

第4章 市场概要

  • 概要
  • 市场动态
    • 促进因素
    • 阻碍因素
    • 机会
  • 全球原发性进行性多发性硬化症治疗药市场分析·预测
  • 波特的五力分析

第5章 主要洞察

  • 主要的M&A
  • 开发平台分析
  • 主要国家的疾病盛行率·发生率
  • 主要产品/品牌分析
  • 主要的研究机关
  • COVID-19对产业的影响(价值链和短期·中期·长期的影响)

第6章 全球原发性进行性多发性硬化症治疗药市场分析·预测:药物各类型

  • 简介·定义
  • 主要调查结果/展开
  • 市场预测
    • 认证核可药
    • 开发平台药物
  • 市场魅力

第7章 全球原发性进行性多发性硬化症治疗药市场分析·预测:各流通管道

  • 简介·定义
  • 主要调查结果/展开
  • 市场预测
    • 零售药局
    • 电子商务
    • 其他
  • 市场魅力

第8章 全球原发性进行性多发性硬化症治疗药市场分析·预测:各地区

  • 主要调查结果
  • 市场预测
    • 北美
    • 欧洲
    • 亚太地区
    • 南美
    • 中东·非洲
  • 市场魅力

第9章 北美的原发性进行性多发性硬化症治疗药市场分析·预测

第10章 欧洲的原发性进行性多发性硬化症治疗药市场分析·预测

第11章 亚太地区的原发性进行性多发性硬化症治疗药市场分析·预测

第12章 南美的原发性进行性多发性硬化症治疗药市场分析·预测

第13章 中东及非洲的原发性进行性多发性硬化症治疗药市场分析·预测

第14章 竞争情形

  • 参与企业:竞争矩阵 (层级·各规模)
  • 企业占有率分析
  • 企业简介
    • F. Hoffmann-La Roche Ltd.
    • Sanofi
    • Mapi Pharma Ltd.
    • Atara Biotherapeutics
    • Takeda Pharmaceuticals International, Inc.
    • AB Science
    • Mallinckrodt
Product Code: TMRGL85270

The report provides revenue of the global primary progressive multiple sclerosis treatment market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global primary progressive multiple sclerosis treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the primary progressive multiple sclerosis treatment market.

The report delves into the competitive landscape of the global primary progressive multiple sclerosis treatment market. Key players operating in the global primary progressive multiple sclerosis treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global primary progressive multiple sclerosis treatment market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Primary Progressive Multiple Sclerosis Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, 2017 - 2031
    • 4.4.1. Market Revenue Projections (US$ Mn)
  • 4.5. Porter's Five Force Analysis

5. Key Insights

  • 5.1. Key Mergers & Acquisitions
  • 5.2. Pipeline Analysis
  • 5.3. Disease Prevalence & Incidence Rate globally with key countries
  • 5.4. Key Product/Brand Analysis
  • 5.5. Major Research Institutes Involved
  • 5.6. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Drug Type, 2017 - 2031
    • 6.3.1. Approved Drugs
    • 6.3.2. Pipeline Drugs
  • 6.4. Market Attractiveness By Drug Type

7. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast By Distribution Channel, 2017 - 2031
    • 7.3.1. Retail Pharmacies
    • 7.3.2. E-commerce
    • 7.3.3. Others
  • 7.4. Market Attractiveness By Distribution Channel

8. Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecasts, By Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast By Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness By Country/Region

9. North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast By Drug Type, 2017 - 2031
    • 9.2.1. Approved Drugs
    • 9.2.2. Pipeline Drugs
  • 9.3. Market Value Forecast By Distribution Channel, 2017 - 2031
    • 9.3.1. Retail Pharmacies
    • 9.3.2. E-commerce
    • 9.3.3. Others
  • 9.4. Market Value Forecast By Country, 2017 - 2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Drug Type
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Drug Type, 2017 - 2031
    • 10.2.1. Approved Drugs
    • 10.2.2. Pipeline Drugs
  • 10.3. Market Value Forecast By Distribution Channel, 2017 - 2031
    • 10.3.1. Retail Pharmacies
    • 10.3.2. E-commerce
    • 10.3.3. Others
  • 10.4. Market Value Forecast By Country, 2017 - 2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Drug Type
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country

11. Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Drug Type, 2017 - 2031
    • 11.2.1. Approved Drugs
    • 11.2.2. Pipeline Drugs
  • 11.3. Market Value Forecast By Distribution Channel, 2017 - 2031
    • 11.3.1. Retail Pharmacies
    • 11.3.2. E-commerce
    • 11.3.3. Others
  • 11.4. Market Value Forecast By Country, 2017 - 2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Drug Type
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country

12. Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Drug Type, 2017 - 2031
    • 12.2.1. Approved Drugs
    • 12.2.2. Pipeline Drugs
  • 12.3. Market Value Forecast By Distribution Channel, 2017 - 2031
    • 12.3.1. Retail Pharmacies
    • 12.3.2. E-commerce
    • 12.3.3. Others
  • 12.4. Market Value Forecast By Country, 2017 - 2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Drug Type
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country

13. Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Drug Type, 2017 - 2031
    • 13.2.1. Approved Drugs
    • 13.2.2. Pipeline Drugs
  • 13.3. Market Value Forecast By Distribution Channel, 2017 - 2031
    • 13.3.1. Retail Pharmacies
    • 13.3.2. E-commerce
    • 13.3.3. Others
  • 13.4. Market Value Forecast By Country, 2017 - 2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Drug Type
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis By Company (2021)
  • 14.3. Company Profiles
    • 14.3.1. F. Hoffmann-La Roche Ltd.
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Company Financials
      • 14.3.1.3. Growth Strategies
      • 14.3.1.4. SWOT Analysis
    • 14.3.2. Sanofi
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Company Financials
      • 14.3.2.3. Growth Strategies
      • 14.3.2.4. SWOT Analysis
    • 14.3.3. Mapi Pharma Ltd.
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Company Financials
      • 14.3.3.3. Growth Strategies
      • 14.3.3.4. SWOT Analysis
    • 14.3.4. Atara Biotherapeutics
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Company Financials
      • 14.3.4.3. Growth Strategies
      • 14.3.4.4. SWOT Analysis
    • 14.3.5. Takeda Pharmaceuticals International, Inc.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Company Financials
      • 14.3.5.3. Growth Strategies
      • 14.3.5.4. SWOT Analysis
    • 14.3.6. AB Science
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Company Financials
      • 14.3.6.3. Growth Strategies
      • 14.3.6.4. SWOT Analysis
    • 14.3.7. Mallinckrodt
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Company Financials
      • 14.3.7.3. Growth Strategies
      • 14.3.7.4. SWOT Analysis

List of Tables

  • Table 01: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 02: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 03: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 04: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 05: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 06: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 08: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 11: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 12: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 13: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 14: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 15: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 16: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 17: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 18: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

List of Figures

  • Figure 01: Global Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
  • Figure 03: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 04: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
  • Figure 05: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 06: Global Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Region, 2021 and 2031
  • Figure 07: Global Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 08: North America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 09: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
  • Figure 10: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 11: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
  • Figure 12: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 13: North America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country, 2021 and 2031
  • Figure 14: North America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 15: Europe Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 16: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
  • Figure 17: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 18: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
  • Figure 19: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 20: Europe Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
  • Figure 21: Europe Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 22: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 23: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
  • Figure 24: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 25: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
  • Figure 26: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 27: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
  • Figure 28: Asia Pacific Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 29: Latin America Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 30: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
  • Figure 31: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 32: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
  • Figure 33: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 34: Latin America Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
  • Figure 35: Latin America Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 36: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 37: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Drug Type, 2021 and 2031
  • Figure 38: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Drug Type, 2022-2031
  • Figure 39: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Distribution Channel, 2021 and 2031
  • Figure 40: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022-2031
  • Figure 41: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Analysis and Forecast, by Country/Sub-region, 2021 and 2031
  • Figure 42: Middle East & Africa Primary Progressive Multiple Sclerosis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 43: Global Primary Progressive Multiple Sclerosis Treatment Market Share Analysis/Ranking, by Company, 2021